EA201700097A1 - Пептид для лечения сахарного диабета 2-го типа и его осложнений - Google Patents
Пептид для лечения сахарного диабета 2-го типа и его осложненийInfo
- Publication number
- EA201700097A1 EA201700097A1 EA201700097A EA201700097A EA201700097A1 EA 201700097 A1 EA201700097 A1 EA 201700097A1 EA 201700097 A EA201700097 A EA 201700097A EA 201700097 A EA201700097 A EA 201700097A EA 201700097 A1 EA201700097 A1 EA 201700097A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- arg
- gly
- glu
- ser
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/15—Corynebacterium
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
Abstract
Изобретение относится к биотехнологии. Представлен аналог эксенатида формулы H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Gly-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-Gly-OH. Изобретение позволяет лечить и проводить профилактику сахарного диабета, а также лечить и проводить профилактику осложнений сахарного диабета 2-го типа, таких как диабетическая нейропатия, мышечная дистрофия и эндотелиопатия.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014134341/10A RU2573933C1 (ru) | 2014-08-21 | 2014-08-21 | Пептид для лечения сахарного диабета 2-го типа и его осложнений |
PCT/IB2015/001614 WO2016027157A1 (en) | 2014-08-21 | 2015-08-04 | Peptide for treatment of type 2 diabetes mellitus and its complications |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201700097A1 true EA201700097A1 (ru) | 2017-06-30 |
Family
ID=54292830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201700097A EA201700097A1 (ru) | 2014-08-21 | 2015-08-04 | Пептид для лечения сахарного диабета 2-го типа и его осложнений |
Country Status (12)
Country | Link |
---|---|
US (1) | US9868773B2 (ru) |
EP (1) | EP3183265B1 (ru) |
JP (1) | JP6442729B2 (ru) |
KR (1) | KR102003619B1 (ru) |
CN (1) | CN106574233A (ru) |
AU (1) | AU2015304934B2 (ru) |
CA (1) | CA2958795C (ru) |
EA (1) | EA201700097A1 (ru) |
ES (1) | ES2711841T3 (ru) |
IL (1) | IL250666B (ru) |
RU (1) | RU2573933C1 (ru) |
WO (1) | WO2016027157A1 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102408480B1 (ko) | 2018-05-30 | 2022-06-10 | 이삼구 | 당뇨질환의 치료용 조성물 |
WO2024077149A2 (en) * | 2022-10-05 | 2024-04-11 | Eli Lilly And Company | Peptides for incretin synthesis |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986000337A1 (fr) * | 1984-06-19 | 1986-01-16 | Transgene S.A. | DERIVES DE L'alpha1-ANTITRYPSINE HUMAINE ET PROCEDE POUR LEUR PREPARATION |
CA1340265C (en) * | 1985-01-18 | 1998-12-15 | Kirston E. Koths | Oxidation resistant muteins |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US20040092443A1 (en) | 1996-08-06 | 2004-05-13 | Yeda Research And Development Co., Ltd | Long-acting exendins and exendin agonists |
AU4063697A (en) | 1996-08-08 | 1998-02-25 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
JP4798814B2 (ja) | 1997-01-07 | 2011-10-19 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 食物摂取低減用のエキセンジンおよびそのアゴニストの使用 |
WO1999007404A1 (en) | 1997-08-08 | 1999-02-18 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
US6703359B1 (en) | 1998-02-13 | 2004-03-09 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
WO1999040788A1 (en) | 1998-02-13 | 1999-08-19 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
JP2002517469A (ja) | 1998-06-12 | 2002-06-18 | バイオネブラスカ,インコーポレイテッド | グルカゴン様ペプチド−1は、耐糖能異常を有する対象におけるグルコースに対するβ細胞応答を改善する |
DE69941510D1 (de) | 1998-08-10 | 2009-11-19 | Us Gov Nat Inst Health | Differenzierung von nicht-insulin in insulin-produzierende zellen durch glp-1 und exendin-4 und dessen verwendung |
RU2247575C9 (ru) | 1999-01-14 | 2005-11-10 | Амилин Фармасьютикалз, Инк. | Способы подавления глюкагона |
ATE460942T1 (de) * | 1999-01-14 | 2010-04-15 | Amylin Pharmaceuticals Inc | Exendine zur glucagon suppression |
US20030087820A1 (en) * | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
CA2396157A1 (en) | 2000-01-10 | 2001-07-19 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia |
CN100480374C (zh) * | 2001-09-28 | 2009-04-22 | 中国科学院上海生命科学研究院 | 制备重组人类胰高血糖素肽-1氨基酸7-37肽段的方法 |
US7105489B2 (en) | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
WO2004016747A2 (en) | 2002-08-14 | 2004-02-26 | University Of Florida | Bone marrow cell differentiation |
AU2003268693A1 (en) | 2002-09-30 | 2004-04-19 | Ajinomoto Co., Inc. | Method of producing stable isotope-labeled protein |
MXPA05003335A (es) | 2002-10-02 | 2005-07-05 | Zealand Pharma As | Compuestos de exendina-4 estabilizados. |
WO2004052390A1 (en) | 2002-12-11 | 2004-06-24 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
US20040209803A1 (en) | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
JP2006514035A (ja) | 2002-12-17 | 2006-04-27 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 心不整脈の予防および治療 |
JP4233029B2 (ja) | 2003-08-27 | 2009-03-04 | 白田 正樹 | マイタケ由来の抽出物およびグリコプロテイン並びにその製造方法 |
CN1989238B (zh) | 2004-05-20 | 2010-05-26 | 味之素株式会社 | 生产琥珀酸的细菌和生产琥珀酸的方法 |
US7442682B2 (en) * | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
JP4595506B2 (ja) * | 2004-11-25 | 2010-12-08 | 味の素株式会社 | L−アミノ酸生産菌及びl−アミノ酸の製造方法 |
PL3524261T3 (pl) * | 2005-08-19 | 2024-04-15 | Amylin Pharmaceuticals, Llc | Eksendyna do stosowania w leczeniu cukrzycy i zmniejszania masy ciała |
JP5252585B2 (ja) | 2006-06-09 | 2013-07-31 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の治療のための化合物 |
CN102827284B (zh) * | 2006-11-14 | 2015-07-29 | 上海仁会生物制药股份有限公司 | 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途 |
HUE027603T2 (en) * | 2007-04-20 | 2016-10-28 | Sigma-Tau Rare Disease Ltd | Stable, recombinant adenosine deaminase |
CN103285379A (zh) * | 2013-06-09 | 2013-09-11 | 南方医科大学 | Glp-1用于制备预防与治疗2型糖尿病大血管并发症的药物的用途 |
US9410225B2 (en) | 2014-05-13 | 2016-08-09 | Teck Resources Limited | Process for recovery of copper from arsenic-bearing and/or antimony-bearing copper sulphide concentrates |
CA2914090C (en) | 2015-03-31 | 2023-08-01 | Allen-Vanguard Corporation | Frequency and time domain streaming receiver |
-
2014
- 2014-08-21 RU RU2014134341/10A patent/RU2573933C1/ru active
-
2015
- 2015-08-04 US US15/504,635 patent/US9868773B2/en active Active
- 2015-08-04 CN CN201580044974.2A patent/CN106574233A/zh active Pending
- 2015-08-04 AU AU2015304934A patent/AU2015304934B2/en active Active
- 2015-08-04 CA CA2958795A patent/CA2958795C/en active Active
- 2015-08-04 JP JP2017529164A patent/JP6442729B2/ja not_active Expired - Fee Related
- 2015-08-04 EP EP15778713.6A patent/EP3183265B1/en active Active
- 2015-08-04 WO PCT/IB2015/001614 patent/WO2016027157A1/en active Application Filing
- 2015-08-04 KR KR1020177007196A patent/KR102003619B1/ko active IP Right Grant
- 2015-08-04 EA EA201700097A patent/EA201700097A1/ru unknown
- 2015-08-04 ES ES15778713T patent/ES2711841T3/es active Active
-
2017
- 2017-02-19 IL IL250666A patent/IL250666B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN106574233A (zh) | 2017-04-19 |
CA2958795A1 (en) | 2016-02-25 |
ES2711841T3 (es) | 2019-05-07 |
CA2958795C (en) | 2021-01-12 |
IL250666A0 (en) | 2017-04-30 |
JP2017525764A (ja) | 2017-09-07 |
EP3183265B1 (en) | 2018-09-26 |
RU2573933C1 (ru) | 2016-01-27 |
US20170240610A1 (en) | 2017-08-24 |
IL250666B (en) | 2021-10-31 |
EP3183265A1 (en) | 2017-06-28 |
AU2015304934A1 (en) | 2017-03-09 |
WO2016027157A1 (en) | 2016-02-25 |
AU2015304934B2 (en) | 2018-05-10 |
KR102003619B1 (ko) | 2019-07-24 |
KR20170041914A (ko) | 2017-04-17 |
JP6442729B2 (ja) | 2018-12-26 |
US9868773B2 (en) | 2018-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA519401435B1 (ar) | مركبات حلقية ثنائية النيوكليوتيد | |
EA201691261A1 (ru) | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b | |
EA201790806A1 (ru) | Иммунорегулирующие средства | |
SA518391864B1 (ar) | مشتقات باي بيرازوليل مفيدة لمعالجة أمراض المناعة الذاتية | |
EA201790413A1 (ru) | Антитела против tigit | |
MX2022005253A (es) | Anticuerpos neutralizantes de poliomavirus. | |
EA201692473A1 (ru) | Способы получения замещенных нуклеотидных аналогов | |
BR112017008672A2 (pt) | anticorpos de il-6 melhorados | |
MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
EA201890185A1 (ru) | Способы лечения опосредованных гепсидином нарушений | |
MX2022015248A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
EA201890572A1 (ru) | Биофармацевтические композиции | |
EA201791249A1 (ru) | Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний | |
EA201990400A1 (ru) | Соединения и композиции и их применение | |
EA201790442A1 (ru) | Трициклические азотсодержащие соединения для лечения инфекции, вызываемой neisseria gonorrhoeae | |
EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
EA201790070A1 (ru) | Бифениламиды, содержащие модифицированные простые эфирные группы, в качестве ингибиторов hsp90 и стимуляторов hsp70 | |
TN2019000106A1 (en) | Novel compounds for treating parasitic disease | |
EA201890543A1 (ru) | Способы и материалы для генной терапии galgt2 | |
PH12016501613B1 (en) | Pyrazines modulators of gpr6 | |
CY1122374T1 (el) | Βιοτινη για την θεραπευτικη αντιμετωπιση απομυελινωτικων νευροπαθειων | |
EA201691498A1 (ru) | Новая мишень для лечения и профилактики диабета | |
EA201700097A1 (ru) | Пептид для лечения сахарного диабета 2-го типа и его осложнений | |
EA201692216A1 (ru) | Пирролидиновые модуляторы gpr40 для лечения заболеваний, таких как диабет | |
EA202191758A1 (ru) | Пептиды для лечения и профилактики диабета и связанных с ним заболеваний |